Bristol Myers Squibb Company is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's mission is to provide transformative therapies in areas such as oncology, immunology, and cardiovascular disease. Bristol Myers Squibb employs a strategy focused on scientific excellence and collaboration, leveraging cutting-edge research and development to address unmet medical needs. Through its robust pipeline and commitment to patient access, the company aims to improve health outcomes and enhance the quality of life for patients worldwide.

BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb (BMY) has demonstrated substantial growth and resilience, reporting annual revenue of $48.3 billion for 2024, bolstered significantly by its oncology and hematology treatment portfolios. Notably, its cancer treatment Opdivo accounted for $9.3 billion of that revenue, while the blood thinner Eliquis emerged as the highest-grossing drug with $13.3...

Bristol-Myers Squibb Reports Strong 2024 Financial Performance with Key Drug Revenue Growth Amidst Market Challenges

Bristol-Myers Squibb has showcased remarkable resilience with a 2024 revenue of $48.3 billion, driven by blockbuster drugs like Eliquis and Opdivo. As the company navigates potential challenges ahead, can its robust pipeline and impressive EPS growth sustain investor confidence?